Zacks Investment Research upgraded shares of Ekso Bionics (NASDAQ:EKSO) from a sell rating to a hold rating in a report published on Tuesday.

According to Zacks, “Ekso Bionics Holdings, Inc. is engaged in designing, developing and selling wearable robots or exoskeletons for the medical, military, industrial and consumer markets. The company’s operating segment consists of Engineering Services and Medical segments. It operates primarily in North America, Western Europe, the Middle East and South Africa. Ekso Bionics Holdings, Inc. is headquartered in Richmond, California. “

Separately, ValuEngine raised shares of Ekso Bionics from a strong sell rating to a sell rating in a report on Friday, November 17th.

Ekso Bionics (EKSO) traded down $0.01 on Tuesday, reaching $2.01. 650,499 shares of the company’s stock were exchanged, compared to its average volume of 1,420,000. The company has a quick ratio of 5.73, a current ratio of 6.09 and a debt-to-equity ratio of 0.18. Ekso Bionics has a 12-month low of $0.99 and a 12-month high of $4.77. The firm has a market cap of $121.01, a price-to-earnings ratio of -2.16 and a beta of 2.01.

Ekso Bionics (NASDAQ:EKSO) last released its earnings results on Wednesday, November 8th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.05). Ekso Bionics had a negative return on equity of 323.00% and a negative net margin of 343.53%. The business had revenue of $1.60 million for the quarter, compared to analyst estimates of $2.40 million. equities analysts forecast that Ekso Bionics will post -0.81 earnings per share for the current fiscal year.

In other Ekso Bionics news, insider Russ Angold sold 50,000 shares of Ekso Bionics stock in a transaction on Wednesday, November 22nd. The shares were sold at an average price of $3.51, for a total transaction of $175,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 3.32% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Carl Domino Inc grew its holdings in Ekso Bionics by 125.2% during the 3rd quarter. Carl Domino Inc now owns 184,788 shares of the company’s stock worth $224,000 after acquiring an additional 102,734 shares during the period. Intellectus Partners LLC grew its holdings in Ekso Bionics by 5.3% during the 2nd quarter. Intellectus Partners LLC now owns 105,294 shares of the company’s stock worth $244,000 after acquiring an additional 5,294 shares during the period. National Planning Corp grew its holdings in Ekso Bionics by 122.2% during the 3rd quarter. National Planning Corp now owns 520,942 shares of the company’s stock worth $620,000 after acquiring an additional 286,492 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Ekso Bionics by 32.9% during the 2nd quarter. Vanguard Group Inc. now owns 711,082 shares of the company’s stock worth $1,650,000 after acquiring an additional 176,197 shares during the period. 6.22% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This piece was reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another site, it was copied illegally and republished in violation of United States and international copyright and trademark law. The original version of this piece can be accessed at

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Africa. The company operates through Medical Devices, Industrial Sales, and Engineering Services segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, hemiplegia due to stroke, and lower limb paralysis or weakness.

Get a free copy of the Zacks research report on Ekso Bionics (EKSO)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Ekso Bionics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ekso Bionics and related companies with Analyst Ratings Network's FREE daily email newsletter.